Management of cardiac hemochromatosis. - Wikidata - awgldk - TriplyDB

Management of cardiac hemochromatosis.

Management of cardiac hemochromatosis.

http://www.wikidata.org/entity/Q55230811

about

Management of cardiac hemochromatosis.

http://www.wikidata.org/entity/Q55230811

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Management of cardiac hemochromatosis.

@en

Management of cardiac hemochromatosis.

@nl

type

label

Management of cardiac hemochromatosis.

@en

Management of cardiac hemochromatosis.

@nl

prefLabel

Management of cardiac hemochromatosis.

@en

Management of cardiac hemochromatosis.

@nl

P1433

Q55230811-4BFDDF1A-A9A1-4FA1-8278-4C5286E61FF9

P1476

Q55230811-A100925A-C843-4BCF-97D8-45E56EBB9675

P2093

Q55230811-D842CD17-07FC-461E-B9B9-09B9F5BE4F5A

P2860

Q55230811-0970285C-8F37-4A80-9CC6-00D7F6F091BA

Q55230811-0F311378-DEF7-480C-A1CF-45CB586DC561

Q55230811-1358C5A6-EE04-4E29-8090-016584FBA2A8

Q55230811-15295C4C-EEFB-4EAE-A289-9EA6D5E24F1B

Q55230811-152F61DF-8EE4-44CE-AFC5-481DD4324FA4

Q55230811-1C2E7654-8B07-4491-8301-F87EF6CE54F7

Q55230811-1EA666BC-7AF1-4380-A5B8-B127ED2994F0

Q55230811-21321F2A-A1D5-4B95-B4B5-883AF0E85062

Q55230811-2354164B-FB75-42BB-AC3E-C73C2E650D6D

Q55230811-252AA778-2855-495D-A7D7-BF37EFB3124B

P304

Q55230811-0AE2FA53-B058-4768-841C-7781993E90BE

P31

Q55230811-B09512F5-2D35-48AD-AD87-BD75EFB63C67

P356

Q55230811-29C65206-6A15-41A7-95B2-B8ECF31B385E

P433

Q55230811-D2FE9EF1-217D-4A80-ACD0-0E1807561F3A

P478

Q55230811-71687ABF-5FEC-462E-A2D0-755D18464F5E

P577

Q55230811-468032E9-C49D-44E8-9EC3-554E3D4F2936

P698

Q55230811-0628A660-1073-4F41-B574-24035226BCDD

P932

Q55230811-193A458F-BDAB-43E7-9EFA-D9D4BA8459C9

P356

AOMS.2017.68729

P1433

Archives of Medical Science

P1476

Management of cardiac hemochromatosis.

@en

P2093

Wilbert S Aronow

http://www.w3.org/2001/XMLSchema#string

P2860

Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice

Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences.

Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment.

Magnetic resonance imaging measurement of iron overload.

The role of Doppler left ventricular filling indexes and Doppler tissue echocardiography in the assessment of cardiac involvement in hereditary hemochromatosis.

Cardiac transplantation in patients with iron overload cardiomyopathy.

Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: polygraphic and echocardiographic evaluation.

Iron overload cardiomyopathy: better understanding of an increasing disorder.

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis.

P304

560-568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5114/AOMS.2017.68729

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29765443

http://www.w3.org/2001/XMLSchema#string

P932

5949916

http://www.w3.org/2001/XMLSchema#string